Only company of its size focused on women’s health
Launching
with a commitment to listen to women to understand her health needs and
help identify solutions that are urgently needed
JERSEY CITY, N.J.-Tuesday 8 June 2021 [ AETOS Wire ]
(BUSINESS
WIRE) -- Organon (NYSE: OGN), today celebrates its launch as a global
women’s health company with employees and women from around the world,
as the Organon executive leadership team rings the opening bell at the
New York Stock Exchange (NYSE). Recognizing the need to listen to and
act on women’s experiences to address the challenges in women’s health,
Organon gathered voices from around the world to create the “Wall of
Voices,” a multimedia installation outside of the NYSE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602006054/en/
Organon
is committed to women’s everyday health needs, with a focus on
reproductive health, health issues that are unique to women, as well as
conditions that disproportionately affect women. The “Wall of Voices”
shares powerful perspectives, voices and images of women from around the
world highlighting these health issues and serves as a symbol of
Organon’s commitment. Women everywhere are invited to take the
“microphone” to add their voice to the digital “Wall of Voices” at
HereForHerHealth.com.
“At Organon, we are here for her health.
Our vision is to create a better and healthier every day for every woman
around the world. There is no other healthcare company with our global
footprint dedicated to putting women at the center that will focus on
identifying medicines and solutions that they so urgently need,” said
Kevin Ali, Chief Executive Officer, Organon. “The time is right for
Organon to bring forward more options for women and healthcare providers
to help shape the future of women’s health.”
Diverse Portfolio will Drive Sustainable Growth
At
launch, Organon’s portfolio will consist of more than 60 medicines and
products across an international footprint that serves people in more
than 140 markets, with nearly 80% of its approximately $6.5 billion in
annual revenue generated outside the U.S. Organon believes it is well
positioned for organic low-to-mid-single digit growth from its 2021 base
of business.
Organon has three core pillars that will benefit from renewed management focus and commercial investment:
Women’s Health: Anchored by NEXPLANON (etonogestrel implant), a
long-acting reversible contraception, along with its contraceptive and
fertility businesses and boosted by its recently announced proposed
acquisition of Alydia Health, a medical device company focused on
preventing maternal morbidity and mortality caused by postpartum
hemorrhage (PPH) or abnormal postpartum uterine bleeding.
Biosimilars: A key growth pillar with products available in various
parts of the world including RENFLEXIS (infliximab-abda) and BRENZYS
(etanercept) in immunology and ONTRUZANT (trastuzumab-dttb) in oncology.
Organon’s expertise is in the commercialization of these products,
bringing them to more people around the world.
Established Brands: 49 well-known products in the respiratory, cardiovascular, dermatology and non-opioid pain areas.
Women at the Center: Organon’s Approach to Innovation
Organon’s
R&D philosophy is to build a business around patient needs, with
the goal of identifying and advancing healthcare options for women that
enable them to live their best lives every day.
“For too long,
for too many common conditions, such as heavy, painful, and irregular
menstrual bleeding, incontinence and menopause and many others, women
have been told to accept and normalize these conditions as a part of
life,” said Sandy Milligan, Head of Organon Research & Development.
“Organon’s mission is to change this. We believe this approach will be
very successful — we hope to discover the ability to identify diseases
earlier, the ability to modify the course of diseases or healthcare
conditions and to ultimately, improve the quality of life for women at
all stages.”
The company’s extensive global capabilities in
clinical development and patient safety, regulatory and medical affairs
make it well-positioned to identify promising drugs, diagnostics and
devices with the greatest potential to impact women’s health.
Majority Female Board of Directors Will Guide Team of Committed Employees
Organon
believes the journey to improve women’s health is foundational to the
gender equity it wants to see in its organization. The representation of
women on the Board — comprising 70% of positions — is higher than any
S&P 500 healthcare company. Together with Organon’s employees, a
global community of approximately 9,000 strong, they are united in their
drive to better support the health of women around the globe.
A live webcast of the Opening Bell from the exchange will be available on the NYSE website today from 9:30 a.m. EST.
About Organon
Organon
(NYSE: OGN) is a global healthcare company formed through a spinoff
from Merck, known as MSD outside of the United States and Canada, to
focus on improving the health of women throughout their lives. Here for
her health, the company has a portfolio of more than 60 medicines and
products across a range of therapeutic areas. Led by the reproductive
health portfolio coupled with an expanding biosimilars business and
stable franchise of established medicines, Organon’s products produce
strong cash flows that will support investments in future growth
opportunities in women’s health, including business development. In
addition, Organon is pursuing opportunities to collaborate with
biopharmaceutical innovators looking to commercialize their products by
leveraging its scale and presence in fast growing international markets.
Organon
has a global footprint with significant scale and geographic reach,
world-class commercial capabilities, and approximately 9,000 employees
with headquarters located in Jersey City, New Jersey.
For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.
Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA
This
news release of Organon & Co. (the “company”) may include
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,”
“estimates,” “will” or words of similar meaning. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. If
underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth
in the forward-looking statements.
Risks and uncertainties
include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the recent global
outbreak of novel coronavirus disease (COVID-19); the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The
company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in the company’s filings with the Securities and Exchange
Commission (SEC), including its registration statement on Form 10,
available at the SEC’s Internet site (www.sec.gov).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602006054/en/
Contacts
Media:
Karissa Peer
(614) 314-8094
Kate Vossen
(732) 675-8448
Investors:
Jennifer Halchak
(201) 275-2711
Edward Barger
(267) 614-4669
Permalink : https://www.aetoswire.com/news/organon-launches-as-new-global-womenrsquos-health-company/en
No comments:
Post a Comment